Immunocore Ltd. and MedImmune, the global biologics research and development arm of AstraZeneca, entered into a second collaboration.
Bayer HealthCare expanded its global clinical development program for the investigational oncology compound copanlisib (BAY 80-6946), which now includes two new phase III studies in indolent non-Hodgkin's lymphomas and one additional phase II study in diffuse large B-cell lymphoma.
The European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI chemotherapy for the treatment of adult patients with wild-type RAS metastatic colorectal cancer.
Merck and Pfizer will begin co-promoting Xalkori in the U.S., Canada, Japan and five European Union countries: France, Germany, Italy, Spain and the U.K.In the U.S. and Canada, Xalkori will be co-promoted by EMD Serono, the US and Canadian biopharmaceutical businesses of Merck.
Rubicon Genomics Inc. extended its clinical supply agreement with Agendia for use of its TransPLEX whole genome RNA amplification technology.
Intrexon Corp. signed a cooperative research and development agreement with NCI for the development of adoptive T cell therapies utilizing the RheoSwitch Therapeutic System platform for the treatment of solid tumor malignancies.
Intrexon Corporation and Merck Serono, the biopharmaceutical arm of Merck KGaA, announced an exclusive collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell cancer therapies.
Merck and Syndax Pharmaceuticals Inc. entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndax's entinostat, an investigational epigenetic therapy, with Merck's Keytruda (pembrolizumab).
Eli Lilly and Co. and OncoMed Pharmaceuticals Inc. entered into an agreement to evaluate the combination of demcizumab and Alimta (pemetrexed for injection) in lung cancer.
MD Anderson Cancer Center and Astellas Pharma Inc. signed an option agreement to research and develop a new treatment for patients with acute myeloid leukemia.
